{"id":"NCT01154140","sponsor":"Pfizer","briefTitle":"A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung","officialTitle":"Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-01-13","primaryCompletion":"2013-11-30","completion":"2016-11-30","firstPosted":"2010-06-30","resultsPosted":"2015-01-05","lastUpdate":"2017-11-06"},"enrollment":343,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non Squamous Lung Cancer"],"interventions":[{"type":"DRUG","name":"treatment","otherNames":[]},{"type":"DRUG","name":"treatment","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the anti-cancer effects of crizotinib when compared with standard chemotherapy in patients with ALK positive lung cancer.","primaryOutcome":{"measure":"Progression-Free Survival (PFS) Based on IRR","timeFrame":"Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)","effectByArm":[{"arm":"Crizotinib","deltaMin":10.9,"sd":null},{"arm":"Chemotherapy","deltaMin":7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":249,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Finland","France","Germany","Hong Kong","India","Ireland","Italy","Japan","Luxembourg","Mexico","Netherlands","Norway","Peru","Portugal","Russia","Singapore","South Africa","South Korea","Spain","Switzerland","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["30822515","30652510","29768118","28373069","27022118","25470694","22316363"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8081014&StudyName=A%20Clinical%20Trial%20Testing%20The%20Efficacy%20Of%20Crizotinib%20Versus%20Standard%20Chemotherapy%20Pemetrexed%20Plus%20Cisplatin%20Or%20Carboplatin%20In%20Patients%20With"]},"adverseEventsSummary":{"seriousAny":{"events":71,"n":171},"commonTop":["Nausea","Vomiting","Diarrhoea","Constipation","Fatigue"]}}